Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Ivosidenib”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04195555
What this trial is testing

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Recurrent EpendymomaRecurrent Ewing SarcomaRecurrent Hepatoblastoma+30 more
National Cancer Institute (NCI) 3
Early research (Phase 1)Study completedNCT03282513
What this trial is testing

AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Who this might be right for
Hepatic Impairment
Agios Pharmaceuticals, Inc. 33
Large-scale testing (Phase 3)Looking for participantsNCT07075016
What this trial is testing

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland 227
Testing effectiveness (Phase 2)Looking for participantsNCT06717958
What this trial is testing

Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation

Who this might be right for
AMLMDS
Technische Universität Dresden 76
Testing effectiveness (Phase 2)Ended earlyNCT05921760
What this trial is testing

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Who this might be right for
IDH1-mutant Cholangiocarcinoma
Servier Bio-Innovation LLC 7
Early research (Phase 1)Study completedNCT02489513
What this trial is testing

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

Who this might be right for
Healthy Volunteers
Agios Pharmaceuticals, Inc. 8
Testing effectiveness (Phase 2)Looking for participantsNCT07392242
What this trial is testing

The Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center 45
Large-scale testing (Phase 3)Study completedNCT02989857
What this trial is testing

Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

Who this might be right for
Advanced CholangiocarcinomaMetastatic Cholangiocarcinoma
Institut de Recherches Internationales Servier 187
Early research (Phase 1)Study completedNCT02073994
What this trial is testing

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Institut de Recherches Internationales Servier 174
Early research (Phase 1)Ended earlyNCT04250051
What this trial is testing

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRecurrent Myeloproliferative Neoplasm+5 more
Northwestern University 2
Early research (Phase 1)Active Not RecruitingNCT05209074
What this trial is testing

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Ductal AdenocarcinomaResectable Pancreatic Cancer
Case Comprehensive Cancer Center 16
Large-scale testing (Phase 3)Looking for participantsNCT06127407
What this trial is testing

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Who this might be right for
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC 136
Testing effectiveness (Phase 2)Looking for participantsNCT04774393
What this trial is testing

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center 84
Testing effectiveness (Phase 2)Looking for participantsNCT07007949
What this trial is testing

A New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaIDH1 Gene MutationIvosidenib
The First Affiliated Hospital of Soochow University 42
Early research (Phase 1)Looking for participantsNCT07006688
What this trial is testing

An IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Who this might be right for
IDH1-Mutated Malignancies
Servier Bio-Innovation LLC 30
Testing effectiveness (Phase 2)Looking for participantsNCT06611839
What this trial is testing

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

Who this might be right for
AMLIDH1 MutationTreatment
Institute of Hematology & Blood Diseases Hospital, China 23
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Testing effectiveness (Phase 2)Looking for participantsNCT04493164
What this trial is testing

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Gene MutationsMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
M.D. Anderson Cancer Center 30
Early research (Phase 1)Study completedNCT03564821
What this trial is testing

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Who this might be right for
IDH1 Mutation Myeloid Neoplasms
Massachusetts General Hospital 18
Large-scale testing (Phase 3)Active Not RecruitingNCT03839771
What this trial is testing

Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
Stichting Hemato-Oncologie voor Volwassenen Nederland 968
Next Page